TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12242054
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mifepristone
Study: 15079120
Drug: Intraoperative intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intercostal nerve blockade with alcohol plus postoperative epidural analgesia with morphine (n=27)
Study: 15079120
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural analgesia with morphine only (n=30)
Study: 11199943
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (valproate) augmentation with haloperidol
Study: 11199943
Drug: Haloperidol alone
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol alone (no-augmentation group)
Study: 11199943
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (valproate) augmentation after 14 days (delayed-augmentation group)
Study: 11199943
Drug: Early-augmentation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-augmentation group
Study: 8676626
Drug: Acamprosate (1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1998 mg daily for bodyweight > 60 kg; 1332 mg daily for ≤ 60 kg)
Study: 30695288
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic prescription
Study: 30695288
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug administration
Study: 29383596
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years
Study: 27629859
Drug: TDF/PI-48w (tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/PI-48w (tenofovir disoproxil fumarate 300 mg/day plus pegylated interferon 180 μg/week for 48 weeks)
Study: 22989707
Drug: Oxytocin discontinuation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin discontinuation (DC)
Study: 19604092
Drug: Clozapine or
Normalized name: clozapine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine or Olanzapine (specific dosage not mentioned)
Study: 17544778
Drug: 20‐mg anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg anterior sub‐Tenon injection of triamcinolone
Study: 17544778
Drug: 20‐mg anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg anterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Study: 17544778
Drug: 40‐mg posterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐mg posterior sub‐Tenon injection of triamcinolone
Study: 17544778
Drug: 40‐mg posterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐mg posterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Study: 14968084
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using verteporfin (Visudyne®)
Study: 11403730
Drug: Nicotine 4-mg
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4-mg gum + cigarette
Study: 11403730
Drug: Nicotine 4-mg
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4-mg gum + unlit cigarette
Study: 11403730
Drug: Nicotine 4-mg
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4-mg gum
Study: 11403730
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups during exercise
Study: 16398726
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilized prophylactic granulocyte transfusions (Cohort G)
Study: 9415540
Drug: Total lymphoid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total lymphoid irradiation plus low-dose prednisone (TLI-LDP)
Study: 3316317
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg nickel sulfate taken once a week for 6 weeks
Study: 3316317
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nickel sulfate taken daily
Study: 30021646
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg/100 mL)
Study: 30021646
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl 100 mL)
Study: 18765433
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg) plus Ezetimibe (10 mg)
Study: 15990426
Drug: Galantamine prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine prolonged-release capsule (PRC) at doses of 16 or 24 mg/day
Study: 15990426
Drug: Galantamine prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine prolonged-release capsule (PRC)
Study: 12723400
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg per day of itraconazole (ITCZ)
Study: 12723400
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg per day of itraconazole (ITCZ)
Study: 10506042
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with 10 mg lignocaine and 40 mg methylprednisolone
Study: 10506042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mg lignocaine)
Study: 10506042
Drug: Non-responders in
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders in control group receiving 40 mg methylprednisolone
Study: 9005799
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg twice a day for 5 days (IV for first 2 days, then oral for next 3 days)
Study: 9005799
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg twice a day for 3 days (oral) + intravenous infusion of 200 mg twice a day for 3 days (for medium disease)
Study: 9005799
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg twice a day for 5 days (for chronic carriers)
Study: 9005799
Drug: Ofloxacin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (dosage not specified)
Study: 6751704
Drug: Budesonide ointment
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide ointment (treated under occlusive dressings for 1 week)
Study: 6751704
Drug: Budesonide ointment
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide ointment (treated for 2 weeks)
Study: 31395484
Drug: Alfaxalone CRI
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 90 minutes (short CRI)
Study: 31395484
Drug: Alfaxalone CRI
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 180 minutes (long CRI)
Study: 31395484
Drug: Alfaxalone bolus
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone bolus (3 mg kg‐1) followed by CRI
Study: 27682229
Drug: Internet-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem-solving treatment (IPST)
Study: 26007680
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of antibiotics (Amoxicillin + Metronidazole)
Study: 21123447
Drug: Low-dose folic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose folic acid (0.4 mg/d)
Study: 15899653
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamins C and E, beta-carotene, and selenium) along with methimazole therapy
Study: 15899653
Drug: Methimazole therapy
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole therapy alone
Study: 2677301
Drug: Flurbiprofen, 50
Normalized name: Flurbiprofen, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 50 mg b.i.d.
Study: 20737210
Drug: Oral 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-aminosalicylic acid (5-ASA) alone
Study: 20737210
Drug: Oral 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-ASA plus oral Lactobacillus casei DG
Study: 20737210
Drug: Oral 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-ASA and rectal Lactobacillus casei DG
Study: 16634751
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg day(-1) for 1 week
Study: 16634751
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1, then 75 mg day(-1)) for 1 week
Study: 16634751
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Clopidogrel
Study: 8629306
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy with a 10-day course of OKT3 (group 2, n = 44)
Study: 8629306
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n = 43)
Study: 8629306
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n = 42)
Study: 8629306
Drug: OKT3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OKT3 therapy (group 2)
Study: 8629306
Drug: LO-Tact-1 therapy
Normalized name: Tact
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LO-Tact-1 therapy (group 3)
Study: 1424170
Drug: Parlodel LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel LAR 25 mg
Study: 1424170
Drug: Parlodel LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel LAR 50 mg
Study: 1424170
Drug: Parlodel LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel LAR 100 mg
Study: 2413294
Drug: Captopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2 mg . kg‐1)
Study: 29307093
Drug: Stopping TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping TNF inhibitors (TNFi) therapy
Study: 29307093
Drug: Continuing TNF
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing TNF inhibitors (TNFi) therapy
Study: 27129011
Drug: Topiramate 75
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 75 mg every 12 hours and Diltiazem 240 mg/day
Study: 27129011
Drug: Topiramate 96
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 96 mg every 12 hours and Hydrochlorothiazide 25 mg/day
Study: 27129011
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg every 12 hours and Propranolol 40-80 mg every 12 hours
Study: 20334647
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Insulin Treatment Questionnaire (IITQ)
Study: 9263086
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefamandole at induction of anesthesia (group 1, n = 24)
Study: 9263086
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefamandole at the beginning of anesthesia followed by an additional dose (2 g) immediately after onset of cardiopulmonary bypass (CPB) (group 2, n = 22)
Study: 9263086
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of cefamandole just at the initiation of anesthesia (group 3, n = 23)
Study: 7508065
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg three times daily
Study: 3533236
Drug: Pancuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.5 mg (approximately 0.007 mg X kg‐1)
Study: 3533236
Drug: Pancuronium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 1.0 mg (approximately 0.015 mg X kg‐1)
Study: 3533236
Drug: d-tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 0.05 mg X kg‐1
Study: 3533236
Drug: d-tubocurarine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 0.1 mg X kg‐1
Study: 26763075
Drug: Sanguinarine (SA)
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguinarine (SA) at 10 mg kg(‐1) BW
Study: 26763075
Drug: Sanguinarine (SA)
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguinarine (SA) at 0, 5, 10 and 20 mg kg(‐1) BW
Study: 22139591
Drug: LTG XR
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG XR 300 mg/day
Study: 22139591
Drug: LTG XR
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG XR 250 mg/day
Study: 16146552
Drug: Simvastatin 5-10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5-10 mg/d for 4 years
Study: 10815342
Drug: Post-assistance programme
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-assistance programme (nine-months with 36 sessions of psychoanalytic group therapy)
Study: 8829887
Drug: Core cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core cooling via intravenous infusion of cold saline
Study: 6531663
Drug: Beta-blockade (propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (propranolol, 100 mg orally)
Study: 30914073
Drug: BD+50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD+50 mg EEO/kg
Study: 30914073
Drug: BD+100 mg
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD+100 mg EEO/kg
Study: 30914073
Drug: BD+150 mg
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD+150 mg OEO/kg
Study: 30914073
Drug: BD+300 mg
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD+300 mg OEO/kg
Study: 29044707
Drug: Cholecalciferol (300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (300,000 IU, two doses at baseline and 8 weeks)
Study: 26998954
Drug: Ilaprazole 5
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 5 mg intravenously
Study: 26998954
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg intravenously
Study: 26998954
Drug: Ilaprazole 20
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20 mg intravenously
Study: 26998954
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg orally
Study: 11820865
Drug: TMZ 10
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 10 mg
Study: 11820865
Drug: TMZ 20
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 20 mg
Study: 11820865
Drug: TMZ 40
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 40 mg
Study: 11820865
Drug: TMZ 80
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 80 mg
Study: 10424325
Drug: Atovaquone alone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone alone (1000 mg)
Study: 10424325
Drug: Atovaquone with
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone with proguanil (1000 mg + 400 mg)
Study: 10424325
Drug: Proguanil alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil alone (400 mg)
Study: 10424325
Drug: Proguanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil with atovaquone (400 mg + 1000 mg)
Study: 7802104
Drug: Low-dose amisulpride
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amisulpride
Study: 2104072
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam intravenously rapidly over 2‐4 s (Group A)
Study: 2104072
Drug: Diazepam intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam intravenously over 1‐2 min, mean dose 15.9 mg (Group B)
Study: 31934844
Drug: Ordinary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary care and treatment in primary care (reference group)
Study: 28244124
Drug: Early endoscopy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endoscopy and possible treatment escalation
Study: 24201169
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous oxygen therapy (TCOT) for 4 weeks as an adjunct to standard care.
Study: 24201169
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous oxygen therapy (TCOT).
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 10 mg
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 20 mg
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 40 mg
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 0.5 mg
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 1.0 mg
Study: 19286091
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 530348 2.5 mg
Study: 17398194
Drug: Ezetimibe/simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/40 mg/day
Study: 18266544
Drug: Functional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Family Therapy (FFT)
Study: 24884894
Drug: Raised fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raised fasting blood glucose or currently on medication for diabetes
Study: 22415888
Drug: Aliskiren 300mg
Normalized name: ALISKIREN 300MG TAB
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300mg plus Losartan 100mg daily for 36 weeks
Study: 22415888
Drug: Losartan 100mg
Normalized name: LOSARTAN 100MG TAB
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 100mg daily for 36 weeks
Study: 12097848
Drug: SonoVue (BR1)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (BR1) at a dose of 1.2 ml
Study: 12097848
Drug: SonoVue (BR1)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (BR1) at a dose of 2.4 ml
Study: 12097848
Drug: SonoVue (BR1)
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SonoVue (BR1) at doses of 0.3, 0.6, 1.2, and 2.4 ml
Study: 7586113
Drug: Atropine 20
Normalized name: Minims Homatropine 20 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 20)
Study: 7586113
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg.kg‐1 alone (n = 21)
Study: 2275907
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine (L)
Study: 29901598
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block using ropivacaine 0.25% 10 mL including dexamethasone 5 mg
Study: 22325115
Drug: Intracervical 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical 2% lidocaine gel
Study: 20455705
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12 mg for women, 15 mg for men) for 18 months
Study: 17039265
Drug: Sequential doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6
Study: 15752394
Drug: Cisatracurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.1 mg kg(‐1))
Study: 15752394
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg kg(‐1))
Study: 15752394
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg kg(‐1))
Study: 2146060
Drug: Isradipine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (twice a day)
Study: 2146060
Drug: Hydrochlorothiazide (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (twice a day)
Study: 21372740
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (group C)
Study: 10497445
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (sIT) applied in 29 patients with pollinosis and 27 patients sensitive to house dust mite.
Study: 10497445
Drug: Routine pharmacotherapy
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pharmacotherapy alone (control group).